- Goodness Growth Holdings has announced that their subsidiary Resurgent Biosciences plans to expand its intellectual property development and clinical research efforts into psychedelic medicine.
Goodness Growth Holdings, Inc. (CSE: GDNS), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences (“Resurgent”), plans to expand its intellectual property development and clinical research efforts into psychedelic medicine. Resurgent is a non-plant/fungus touching-entity and does not intend to engage directly in the cultivation, manufacture, or distribution of any psychedelics.
“Our formation of Resurgent Biosciences was a strategic move to separate our multi-state cannabis company from the non-plant-touching, ancillary business opportunities within our intellectual property portfolio… Resurgent has proven its ability to conduct clinical research of medicinal plants in partnership with leading hospitals across the United States, and we have also made substantial progress to commercialize several of the technological innovations in our IP portfolio, including our patent-pending TerpSafe™ packaging technology and multi-channel vaporizer.”
Chairman and Chief Executive Officer, Kyle Kingsley, M.D.
Launch of TerpSafe™ Technology to Broader Markets
The Company also announced the launch of its TerpSafe™ packaging technology to broader cannabis markets across North America. TerpSafe™ packaging was designed for consumers who demand ultimate freshness of cannabis flower, and its technology has been proven to preserve 100 percent of the terpene content of flower for more than six weeks, compared to a control group which lost more than 30 percent of terpene content within four weeks of packaging.
TerpSafe™ packaging represents the first commercialized product available for sale from the Resurgent Biosciences IP portfolio, and it is being manufactured and distributed under a licensing agreement with